Optimizing the Approach of Mobile Application Use to Improve Medication Adherence in Patients With Hypertension
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Mercer University
- Enrollment
- 55
- Primary Endpoint
- Blood pressure
Study Overview
Brief Summary
The purpose of this study was to determine the effectiveness of using a custom-designed mobile application to improve blood pressure (BP) and promote adherence to antihypertensive medication regimens. This was a prospective, multicenter, randomized controlled trial. Patients were randomized to an intervention or control group for three months. Antihypertensive medication refill history was assessed three months before, during and three months after the study period. Continuous outcome measures investigated were systolic/diastolic BP and medication refill history, using the cumulative medication gap (CMG) score.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years of age
- •Diagnosed with hypertension as evidenced by diagnosis codes or chart documentation
- •Prescribed at least one antihypertensive for a minimum of three months prior to enrollment
- •Have access to an Android mobile device with data capabilities
- •Consent to using the application on their device
Exclusion Criteria
- •Do not read or speak English
- •Unable to read and sign the informed consent or Health Insurance Privacy and Accountability Act (HIPAA) waiver
- •Too ill or cognitively impaired to participate
Arms & Interventions
Control
Intervention
Mobile application intervention
Intervention: Mobile application (BP-n-Me) (Other)
Outcomes
Primary Outcomes
Blood pressure
Time Frame: 6 months
This was assessed by measuring the change of systolic and diastolic blood pressure
Medication adherence
Time Frame: 6 months
This was assessed based on cumulative medication gap (CMG)
Secondary Outcomes
No secondary outcomes reported